^
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive
:
C3
Am J Cancer Res - 3wk
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 4wk
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 4wk
MRE11A underexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant
:
C3
AACR 2021 - 4wk
UBQLN4 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin
Resistant
:
C3
AACR 2021 - 4wk
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
EGFR overexpression
Esophageal Squamous Cell Carcinoma
erlotinib
Sensitive
:
B
No biomarker
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
B
NTRK3 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive
:
C1
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C1
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive
:
C1
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C2
NDRG1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant
:
C3
SGK1 overexpression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Resistant
:
C3
AFAP1-AS1 overexpression
Esophageal Squamous Cell Carcinoma
FP
Resistant
:
C3
PD-L1 expression
Esophageal Squamous Cell Carcinoma
camrelizumab
Sensitive
:
C3
TLR signature
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
C3
NDRG1-H
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab + DKN-01
Sensitive
:
C3
DKK1 overexpression
Esophageal Squamous Cell Carcinoma
DKN-01
Sensitive
:
C3
NFKB1 expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive
:
C3
KDR expression
Esophageal Squamous Cell Carcinoma
rivoceranib
Sensitive
:
C3
PD-L1 overexpression + CCL5 overexpression
Esophageal Squamous Cell Carcinoma
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive
:
C3
TTN D7145H
Esophageal Squamous Cell Carcinoma
cisplatin
Sensitive
:
C3
MYH4 Q1210fs
Esophageal Squamous Cell Carcinoma
cisplatin
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our